CanSino Biologics
continues advancing its proprietary mRNA vaccine platform, reporting Phase II safety and immunogenicity data for its CS-2034 mRNA vaccine in Chinese adults, building on its earlier position as a global pioneer of adenoviral-vector vaccines.
- Country
- China
mrna-platform
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Drug & vaccine development | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.